Q2 report due on 15 July Expect continued y-o-y growth, but not as strong as in Q1 Lower ’22 EBITA ...
Finepart meddelade under fredagen den 8 juli att bolaget erhållit en order från Wiretonic AB, ett fö...
Cut to Q2e on lagged price increases and softer demand We cut ’22e-’24e EBITA by 6-5%, on tougher e...
Redeye's preliminary revisions suggest increased forecasts and Base Case following Hexatronic’s prel...
We keep our estimates unchanged ahead of Q2 Higher uncertainty for retailers, but long-term case int...
The news is welcome as the 50-patient European PAES study expands the European reference clinics and...
Redeye has a positive take on the news that Antti Vuolanto, currently COO, has been named as CEO of ...
Solid underlying momentum likely to continue in Q2 and largest acquisition ever completed in July Ad...
Redeye updates its estimates for Q2. Sales estimates are raised mainly due to FX tailwind and the in...
Redeye comments on the outcome of the completed rights issue and adjust its fair value range accordi...
Q2 report due on July 28 We expect sales of EUR 309m and adj.
Transactions and high net letting offset top-line miss Higher reported interest rate explains CEPS r...
Redeye continues to have a positive outlook on Waystream even after a slightly weaker report than we...
Net operating income -3% vs. ABGSCe Net leasing (TTM) was SEK 74m (17m in Q2) +2% vs.
Q2e EBIT of SEK 159m Pulp prices at ATH, but more supply into ‘23e Fair value range of SEK 10-15/sha...
High out-of-pocket costs cut growth in ‘09-10 (GFC) Caution reflected in estimates; 35x ‘22e EV/EBI...
Redeye ser positivt på nyheten att FDA accepterat Eisais registreringsansökan för Lecanemab under de...
Redeye is encouraged by Cereno Scientific announcing first-patient-in for its phase II study with le...
Q2 report due on 15 July We expect sales of SEK 444m and EBITA of 66m We lower our ’23-24e EBITA by ...
Q2 report due on 15 July We expect sales of SEK 222m and EBIT of SEK 27m Share trading at EV/EBIT 8.
